Model-Informed Precision Dosing of Antibiotics in Pediatric Patients: A Narrative Review.
Alan Abdulla, Elma E Edwina, Robert B Flint...
https://pubmed.ncbi.nlm.nih.gov/33708753/Actively Recruiting
Led by Karolinska Institutet · Updated on 2025-11-21
30
Participants Needed
2
Research Sites
8 weeks
Total Duration
This research aims to explore whether model-informed precision dosing MIPD can help optimize the drug levels of tuberculosis TB medications during early treatment in adults with drug-susceptible pulmonary tuberculosis. The study investigates if current dosing guidelines combined with MIPD can support timely dose adjustments to improve treatment outcomes. The focus is on first-line TB drugs including rifampicin, isoniazid, pyrazinamide, and ethambutol. Participants will receive standard TB treatment following national care programs, with MIPD used as a clinical support tool to predict drug exposure and recommend dose adjustments early in therapy. This observational study does not involve administering experimental treatments but rather monitors how MIPD influences dosing decisions and drug concentrations. Drug levels will be measured during treatment to compare predicted versus actual concentrations and to assess the effectiveness of dose optimization. Throughout the study, participants will have pharmacokinetic sampling to monitor drug levels, with dose recommendations provided within the first five days after sampling. Researchers will evaluate the proportion of patients whose doses are adjusted based on predictions, the accuracy of the model in estimating drug exposure, and overall target drug levels achieved during approximately one month of treatment. The study includes informed consent and ongoing observation of participants receiving TB care over this period.
CONDITIONS
DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis
L
Lina Davies Forsman, MD, PhD, Associate Professor
K
Katarina Niward, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Karolinska Institutet
Lead Sponsor
Karolinska University Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 month
Participants who undergo routine care for pulmonary tuberculosis are observed to evaluate dosing by Model-Informed Precision Dosing (MIPD).
Weekly visits for up to 4 weeks
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Alan Abdulla, Elma E Edwina, Robert B Flint...
https://pubmed.ncbi.nlm.nih.gov/33708753/Junichi Azuma, Masako Ohno, Ryuji Kubota...
https://pubmed.ncbi.nlm.nih.gov/23150149/Katarina Niward, Lina Davies Forsman, Judith Bruchfeld...
https://pubmed.ncbi.nlm.nih.gov/30124844/Jotam G Pasipanodya, Helen McIlleron, André Burger...
https://pubmed.ncbi.nlm.nih.gov/23901086/Karolinska Institutet
Lead Sponsor
Karolinska University Hospital
Collaborating Sponsor